Kleanthis g. xanthopoulos
WebAug 24, 2024 · Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies, which Kleanthis G. Xanthopoulos, Ph.D., chairman and CEO, believes is one-of-a-kind. This summer’s deals with Kite Pharmaceuticals, a Gilead Company, and BeiGene – totaling $4 billion and boasting ... WebMay 13, 2024 · The latest Tweets from K.G. Xanthopoulos (@KleanthisX): "Very stormy San Francisco at JPMorgan. Deal get done regardless 😇"
Kleanthis g. xanthopoulos
Did you know?
WebDec 3, 2007 · Xanthopoulos is the co-founder and former President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. "Kleanthis has had a distinguished and broadly … WebJun 15, 2024 · Kleanthis Xanthopoulos is 62, he's been the Independent Director of Zosano Pharma Corp since 2013. There are 1 older and 7 younger executives at Zosano Pharma …
WebKleanthis G. Xanthopoulos, Ph.D. is the President & Chief Executive Officer of Regulus Therapeutics Inc. joining Regulus around its formation in 2007. Prior to that, he was a … WebJul 22, 2011 · Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics, talking on the impact of microRNA medicines
WebJan 7, 2016 · IRVINE, Calif., Jan. 7, 2016 /PRNewswire/ -- Bioniz Therapeutics, Inc., a biopharmaceutical company developing first-in-class multi-cytokine inhibitory … WebJan 19, 2024 · Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies. …
WebKleanthis Xanthopoulos was born on 04/15/1958 and is 64 years old. Kleanthis Xanthopoulos lives in La Jolla, CA; previous cities include Solana Beach CA and Rancho …
WebKleanthis G Xanthopoulos is Board Member at Irras AB. See Kleanthis G Xanthopoulos's compensation, career history, education, & memberships. prayer renewal networkWebApr 10, 1998 · Kleanthis G. Xanthopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). Transgenomic viruses Patent number: 6238858 sciunison food driveWebNov 12, 2024 · SAN DIEGO and TAICANG, SUZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the d... sciullo wiesbadenWebApr 10, 1998 · Kleanthis G. Xanthopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents … prayer renewal osrsWebMay 7, 2024 · It has been our stated ambition to carry out a change of listing venue to Nasdaq Stockholm Main Board during 2024 to raise the company's profile and deliver shareholder value, and this transition will further strengthen the quality associated with IRRAS," said Kleanthis G. Xanthopoulos, Ph.D., President & CEO of IRRAS. scius forum 12thWebIntroducing IRRA flow®. IRRA flow Advantages. Active Fluid Exchange. Integrated, Continuous Pressure Monitoring. Potential to Reduce Occlusions & Infections. Easy Integration in Clinical Practice. Introducing Hummingbird. Hummingbird Quad ICP Monitoring with Drainage. Hummingbird Solo ICP Monitoring. sciullis pittsburghWebJun 1, 2015 · LA JOLLA, Calif., June 1, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. ( NASDAQ: RGLS ), a biopharmaceutical company leading the discovery and development … sciullo engineering services